1. RxSight's stock is under investigation following significant investor losses. 2. The company reported Q2 2025 revenue declines and lowered future guidance. 3. RxSight's stock price fell 37.8% on July 9, 2025, due to poor results. 4. Faruqi & Faruqi is encouraging affected investors to contact them for legal options. 5. Adoption challenges were cited as a reason for declining revenues.
The significant drop in stock price and lowering of guidance indicate deep investor concern. Historical examples show that similar patterns often result in long-term price struggles.
Given the scale of the investigation and stock performance, it significantly affects RXST's price outlook.
Ongoing legal investigations and operational challenges can hinder recovery, influencing investor confidence long-term.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In RxSight To Contact Him Directly To Discuss Their Options
If you suffered significant losses in RxSight stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company's Chief Executive Officer, Ronald Kurtz, disclosed that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."
On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, on unusually heavy trading volume.
To learn more about the RxSight investigation, go to www.faruqilaw.com/RXST or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909724867/en/
Faruqi & Faruqi, LLP
Josh Wilson
877-247-4292 or 212-983-9330 (Ext. 1310)